Pharma R&D Today
Ideas and Insight supporting all stages of Drug Discovery & Development
Posted on June 6th, 2016 by Jeffrey Paul, PhDPharma R&D
Innovative drug targets are necessary if precision medicine is to become the norm. Collaboration will be the enabler in developing novel drug therapies: (more…)
Posted on May 27th, 2016 by J.-P. Clement MDPharmacovigilance
We usually tend to think that our overall compliance to regulations and fulfilling our ethical commitment to patient safety is best answered through an established set of Policies and SOPs. We design processes around regulatory mandates and adjust to the complexity of the enterprise as much as we can, feeling confident that all our bases are covered. (more…)
Posted on May 26th, 2016 by Ros CheethamChemistry
Re-purposing of drugs is fraught with challenges, but can they be overcome so that patients benefit? The term re-purposing is often associated with the idea of saving a few bucks by taking something old and turning it into something useful (like transforming an empty wine bottle into a bird feeder). In the pharmaceutical world, though (more…)
Posted on May 25th, 2016 by Tamas SzarvasPharma R&D
As a senior strategic marketing professional at Elsevier, I often find myself telling our potential clients: to unlock your organization’s productivity, you need to strengthen your science—and we can help you do that. (more…)
Posted on May 24th, 2016 by Jaqui HodgkinsonPharma R&D
Big data have huge potential in pharmaceutical research, especially now that the technology to manage, mine and assess the vast amount of available information is catching up with the reality of researchers’ needs. Where it once would have taken many months to effectively trawl (more…)
About this Blog
The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.
Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier, its affiliates and sponsors or its parent company, Reed Elsevier.